



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium**

#### **Citation for published version:**

Ruscito, I, Cacsire Castillo-tong, D, Vergote, I, Ignat, I, Stanske, M, Vanderstichele, A, Ganapathi, RN, Glajzer, J, Kulbe, H, Trillsch, F, Mustea, A, Kreuzinger, C, Benedetti Panici, P, Gourley, C, Gabra, H, Kessler, M, Sehoul, J, Darb-esfahani, S & Braicu, EI 2017, 'Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium' *European Journal of Cancer*, vol 79, pp. 214-225. DOI: 10.1016/j.ejca.2017.04.016

#### **Digital Object Identifier (DOI):**

[10.1016/j.ejca.2017.04.016](https://doi.org/10.1016/j.ejca.2017.04.016)

#### **Link:**

[Link to publication record in Edinburgh Research Explorer](#)

#### **Document Version:**

Peer reviewed version

#### **Published In:**

*European Journal of Cancer*

#### **Publisher Rights Statement:**

This is the authors final peer-reviewed manuscript as accepted for publication.

#### **General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

#### **Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 **Exploring the clonal evolution of CD133/ALDH1-positive cancer**  
2 **stem-like cells from primary to recurrent high-grade serous ovarian**  
3 **cancer (HGSOC). A study of the OCTIPS Consortium.**

4

5 Ilary RUSCITO<sup>#1,2,3</sup>, Dan CACSIRE CASTILLO-TONG<sup>4</sup>, Ignace VERGOTE<sup>5</sup>, Iulia  
6 IGNAT<sup>1</sup>, Mandy STANSKE<sup>6</sup>, Adriaan VANDERSTICHELE<sup>5</sup>, Ram N.  
7 GANAPATHI<sup>7</sup>, Jacek GLAJZER<sup>1</sup>, Hagen KULBE<sup>1</sup>, Fabian TRILLSCH<sup>8,9</sup>, Alexander  
8 MUSTEA<sup>10</sup>, Caroline KREUZINGER<sup>4</sup>, Pierluigi BENEDETTI PANICI<sup>2</sup>, Charlie  
9 GOURLEY<sup>11</sup>, Hani GABRA<sup>12</sup>, Mirjana KESSLER<sup>13</sup>, Jalid SEHOULI<sup>1</sup>, Silvia  
10 DARB-ESFAHANI<sup>6</sup>, Elena Ioana BRAICU<sup>1</sup>.

11

12 1.Department of Gynecology, European Competence Center for Ovarian Cancer,  
13 Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger  
14 Platz 1, D-13353 Berlin, Germany.

15 2.Department of Gynecology, Obstetrics and Urology, Sapienza University of Rome,  
16 Rome, Italy.

17 3.Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.  
18 [ilary.ruscito@uniroma1.it](mailto:ilary.ruscito@uniroma1.it)

19 4.Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical  
20 University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

21 5.Division of Gynaecological Oncology, Leuven Cancer Institute, Department of  
22 Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke  
23 Universiteit Leuven, Herestraat 49, B-3000 Leuven, Belgium.

24 6.Institute of Pathology, Charite Medical University, Berlin, Campus Mitte, Germany.

25 7.Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas  
26 HealthCare System, Charlotte, NC, USA.

27 8.Department of Gynecology and Obstetrics, University of Munich,  
28 Marchioninistrasse 15, Munich, Germany.

29 9. Department of Gynecology and Gynecologic Oncology, University Medical Center  
30 Hamburg-Eppendorf, Martinistr. 46, Hamburg, Germany.

31 10.Department of Gynecology and Obstetrics, University Medicine of Greifswald,  
32 Greifswald, Germany.

33 11. Nicola Murray Centre for Ovarian Cancer Research, University of Edinburgh  
34 Cancer Research UK Centre, MRC IGMM, Western General Hospital, Crewe Road  
35 South, Edinburgh EH4 2XR, UK.

36 12. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer,  
37 Imperial College London, London, UK.

38 13. Department of Molecular Biology, Max Planck Institute for Infection Biology,  
39 Berlin, Germany.

40

41

42

43 **#Corresponding Author:** Ilary Ruscito, MD

44 Department of Gynecology, European Competence Center for Ovarian Cancer,  
45 Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger  
46 Platz 1, D-13353 Berlin, Germany.

47 Phone. +49 (0) 30 450 564 476

48 Fax. +49 (0) 30 450 564 939

49 Email address: [ilary.ruscito@uniroma1.it](mailto:ilary.ruscito@uniroma1.it)

50

51

52 **Role of the Funding Source**

53 European Community's Seventh Framework Program supported this study under the  
54 grant agreement No. 279113-2 (OCTIPS).

55

56

57 **ABSTRACT**

58 **Background:**High-grade serous ovarian cancer (HGSOC) causes 80% of all OC  
59 deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear. In  
60 particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC)  
61 HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and  
62 aldehyde dehydrogenase-1(ALDH1) CSC biomarker expression in pOC and rOC  
63 HGSOCs.

64 **Methods:**224 pOC and rOC intra-patient paired tissue samples derived from 112  
65 HGSOC patients(pts) were evaluated for CD133 and ALDH1 expression using IHC.  
66 pOCs and rOCs were compared for CD133 and/or ALDH1 levels. Expression profiles  
67 were also correlated with patients' clinico-pathological and survival data.

68 **Results:**49.1%(55/112) and 37.5%(42/112) pOCs were CD133+ and ALDH1+,  
69 respectively. CD133+ and ALDH1+ samples were detected in 33.9%(38/112) and  
70 36.6%(41/112) rOCs. CD133/ALDH1 coexpression was observed in 23.2%(26/112)  
71 and 15.2%(17/112) of pOCs and rOCs, respectively. Pairwise analysis showed a  
72 significant shift of CD133 staining from higher (pOCs) to lower expression levels  
73 (rOCs)( $p < 0.0001$ ). Furthermore, all CD133+pOC pts were FIGO-stage III/IV  
74 ( $p < 0.0001$ ) and had significantly worse PFI( $p = 0.04$ ) and OS( $p = 0.02$ ). On multivariate  
75 analysis, CD133/ALDH1 coexpression in pOCs was identified as independent  
76 prognostic factor for PFI (HR:1.64;95%CI:1.03-2.60; $p = 0.036$ ) and OS  
77 (HR:1.71;95%CI:1.01-2.88; $p = 0.045$ ). Analysis on 52 pts with known somatic BRCA  
78 status revealed that BRCA mutations did not influence CSC biomarker expression.

79 **Conclusions:**The study showed that CD133/ALDH1 expression impacts HGSOC pts'  
80 survival and firstly suggests that CSCs might undergo phenotypic change during the

81 disease course similarly to non stem-like cancer cells, providing also a first evidence  
82 that there is no correlation between CSCs and BRCA status.

83

84

85 **Key Words:** Ovarian Cancer; CD133; ALDH1; Aldehyde dehydrogenase-1; cancer  
86 stem-like cell; BRCA; prognosis; survival.

87

## 88 INTRODUCTION

89 Ovarian cancer (OC) remains the most lethal gynecologic malignancy[1]. Advances  
90 in cancer genomics, epigenomics and proteomics has led to the understanding that OC  
91 is a heterogeneous group of different tumors displaying distinct phenotypes and  
92 etiology[2,3]. The current dichotomous OC classification[4,5] groups these tumors in  
93 two distinct categories: Type I (low-grade serous-papillary, low-grade endometrioid,  
94 mucinous and clear-cell carcinomas) and Type II (high-grade serous-papillary, high-  
95 grade endometrioid, carcinosarcomas and undifferentiated tumors). Type II OCs show  
96 a more aggressive biological behavior, are diagnosed at advanced stage and are  
97 chromosomally highly unstable. Among them, high-grade serous OC (HGSOC)  
98 accounts for around 80% of all OC deaths[3]. The identification of predictive  
99 biomarkers is pivotal for designing new treatment strategies able to reduce HGSOC-  
100 related mortality. In this context, the cancer stem-like cell (CSC) theory represents  
101 one model to investigate OC heterogeneity. This hypothesis, supported by increased  
102 evidence acquired in the last decade, proposes that, within OC tissues, a small  
103 population of cells has an increased capacity for self-renewal, tumorigenesis and  
104 differentiation[6]. In multiple experimental studies CSCs showed to increase potential  
105 of tumorigenesis, metastasis/invasion, neoangiogenesis and chemoresistance[7,8] and  
106 have been often correlated with a poor prognosis[9-13].

107 Several potential CSC markers have been identified in OC samples[14-15]. Among  
108 them, aldehyde dehydrogenase-1 (ALDH1) and CD133 are currently the best  
109 characterized for ovarian CSCs. Their expression on the cell surface is associated with  
110 increased tumorigenesis and self-renewal capability [16-18]. Nevertheless, the clonal  
111 evolution of CSCs throughout the course of disease, from primary (pOC) to recurrent

112 (rOC) OC, has not been elucidated yet and information about the changes in CSC  
113 presence within the tumor after relapse is still lacking.

114 The aim of this study was to investigate the evolution of CSC biomarkers CD133 and  
115 ALDH1 expression in a large series of paired primary and recurrent HGSOCs.

116

## 117 **MATERIALS AND METHODS**

### 118 Sample Collection

119 224 paired samples from 112 HGSOC patients were collected during primary and  
120 secondary tumor debulking. Patients were included consecutively and have been  
121 treated between 1985 and 2013 through primary cytoreduction followed by platinum-  
122 based chemotherapy. Patients, retrospectively selected from the OCTIPS (Ovarian  
123 Cancer Therapy–Innovative Models Prolong Survival, Agreement No.279113-2)  
124 Consortium database, were treated for both pOC and rOC in one of the European  
125 Gynecologic Oncology Referral Centers of the following Institutions: Charité  
126 Universitätsmedizin Berlin,Germany; Katholieke Universiteit Leuven,Belgium;  
127 Imperial College, London,UK; University of Edinburgh,UK.

128 Inclusion criteria were: having experienced at least one OC relapse for which having  
129 been subjected to at least one palliative surgery. Exclusion criterion was: no cancer  
130 tissue available from both pOC and rOC. Approval from each local ethics committee  
131 was obtained (EK207/2003,ML2524,05/Q0406/178,EK130113,06/S1101/16). OC  
132 tissue samples were collected during primary cytoreduction and at the surgery for  
133 relapse. All included samples underwent central histopathological assessment to  
134 confirm the diagnosis of HGSOC and to evaluate the tissue quality and tumor contain.

### 135 Immunohistochemistry

136 Immunohistochemical staining was performed on tissue microarrays (TMAs).

137 Slides were deparaffinized in xylol, rehydrated in graded alcohol and boiled in a  
138 pressure cooker for 5 minutes in citrate buffer (pH=6) for ALDH1 staining or in  
139 EDTA (pH=9) for CD133 staining. Mouse anti-human ALDH1-antibody (clone  
140 44;BD Transduction Laboratories, Franklin Lakes, NJ, USA) and mouse anti-human  
141 CD133/1-antibody (AC133 clone; Miltenyi-Biotec, Bergisch Gladbach, Germany)  
142 were diluted 1:500 and incubated on the slides for 60 minutes at room temperature.  
143 Bound antibodies were visualized using DAKO Real Detection System and DAB+  
144 (3,3'-diaminobenzidine; DAKO, Glostrup, Denmark) as a chromogen. Finally, the  
145 slides were co-stained with hematoxylin.

146 CD133 stained samples were assessed basing on the number of stained tumor cells.  
147 Samples were classified as “CD133-negative” (<10% CD133 positive tumor cells) and  
148 “CD133-positive” (>10% CD133-positive tumor cells) [19-20].

149 For ALDH1 staining evaluation, as previously published [21-22], the number of  
150 stained tumor cells (0%=0; 1-10%=1; 11-50%=2; >50%=3) was multiplied with the  
151 intensity of staining (negative=0; weak=1; moderate=2; strong=3), resulting in a  
152 semiquantitative immunoreactivity score (IRS) that ranged from 0 to 9. For further  
153 analysis, samples were classified “ALDH1-negative”, for absent or weak focal  
154 staining (IRS=0-1), or “ALDH1-positive”, for ALDH1-high tumor expression (IRS=2-  
155 9).

156 All samples were evaluated independently by two co-authors (IR and SDE).

### 157 Clinical Data and Follow-up

158 Patients' clinical data and information on 52 patients' germline and/or somatic BRCA  
159 status were retrieved from OCTIPS Consortium database [23-24]. Platinum-  
160 resistance and platinum-sensitivity were defined, according to GCIG, as relapse  
161 occurring before or after six months following the last platinum-based chemotherapy,



162 respectively[25]. Recurrence was defined basing on RECIST Criteria[26]. A sole  
163 CA125 serum elevation was not considered relapse[27].

#### 164 *Statistical Analysis*

165 Statistical analysis was performed using SPSS version 22.0(SPSS Inc, Chicago, IL,  
166 USA). To assess the difference between pOCs and rOCs in terms of biomarker  
167 expression, the correlation test (Spearman coefficient, 2-tailed) and the “Wilcoxon  
168 signed rank” non-parametric test for related samples were applied. Correlation of  
169 CD133 and ALDH1 tumor expression with patients’ clinico-pathological categorical  
170 data was assessed using the Fisher’s exact test. Patients’ progression-free  
171 interval(PFI), progression-free survival (PFS) and overall survival(OS) were  
172 determined by Kaplan–Meier analysis (Log-Rank test).PFI represented the time  
173 interval from the last adjuvant chemotherapy to relapse, whereas progression-free  
174 survival (PFS) was the time interval between first recurrence diagnosis and tumor  
175 progression. For univariate and multivariate survival analyses, the Cox regression  
176 model was used. Multivariable models were performed among variables reporting a  
177 p-value $\leq$ 0.1 in univariate analysis. P values $\leq$ 0.05 were considered statistically  
178 significant.

179

## 180 **RESULTS**

181 Primary and recurrent intra-patient paired tumor samples derived from 112 HGSOc  
182 patients were analyzed for CD133 and ALDH1 expression. Patients’ characteristics  
183 are listed in **Table 1**.

184 Immunohistochemistry staining showed that ALDH1 and CD133 proteins were  
185 localized to the cytoplasm(**Fig1, Fig.3**).

186

187

188 CD133 expression.

189 CD133-positive (CD133<sup>+</sup>) staining was significantly more frequent among  
190 pOCs[55/112(49.1%)] compared to rOCs[38/112(33.9%)], p=0.030(Fisher's exact  
191 test,**Fig.1a,1c**). Investigation of sequential changes in CD133<sup>+</sup> expression in paired  
192 tumors, with a correlation test (Spearman coefficient) between pOCs and rOCs,  
193 demonstrated a significant correlation (p=0.001,Spearman coefficient 0.306).  
194 Furthermore, pairwise testing revealed a significant shift from higher frequency of  
195 CD133<sup>+</sup> cells in pOCs to lower levels in the paired recurrent samples (p<0.0001,  
196 Wilcoxon test;**Fig.2**), thus indicating significantly higher rates of CD133<sup>+</sup> cells in  
197 pOCs compared to rOCs.

198 ALDH1 expression.

199 Distribution of ALDH1 IRS in pOCs and rOCs is shown in **Fig.3a,3d**. ALDH-1  
200 positive tumors were found in 37.5%(42/112) and 36.6%(41/112) of primary and  
201 recurrent samples, respectively (p=1,Fisher's exact test,**Fig.3b,3e**). A trend for  
202 significant correlation between pOCs and rOCs ALDH1-expression levels was seen  
203 (p=0.059,Spearman coefficient 0.179). Pairwise analysis showed no tendency towards  
204 a change of IRS values to higher or lower levels in recurrences (p=0.988,Wilcoxon  
205 test;**Fig.4**).

206 CD133/ALDH1 co-expression.

207 Co-expression of both CSCs biomarkers was detected in 23.2%(26/112) of pOCs and  
208 in 15.2%(17/112) of rOCs(p=0.174,Fisher's exact test). Among 26 patients reporting  
209 CD133/ALDH1 co-expression in pOCs, 22(84.6%) lost this pathological  
210 characteristic in relapse situation. Of the 17 patients presenting biomarker co-  
211 expression in rOC, 13(76.5%) showed no co-expression in pOC. Consequently, 4/112

212 patients (3.6%) showed CD133/ALDH1 co-expression in both pOC and rOC: two of  
213 them were platinum-resistant and two were platinum-sensitive.

#### 214 CSCs biomarkers and clinico-pathological factors

215 We analyzed the correlation of ALDH1 and/or CD133 tumor expression patterns in  
216 pOCs with patients' clinico-pathological characteristics. All primary CD133<sup>+</sup> patients  
217 were diagnosed at FIGO III/IV stage (p=0.006). No correlation was observed between  
218 other clinico-pathological factors and ALDH1 and/or CD133 tumor  
219 expression(**Tab.2**).

#### 220 Survival

221 CD133 positivity in pOCs was significantly associated with poor PFI and OS  
222 (**Fig.5a,5b**). In particular, CD133<sup>+</sup> and CD133<sup>-</sup> patients reported median OS of 51 and  
223 71 months (HR:1.713;95%CI:1.076-2.727;p=0.02) and median PFI of 9 and 17  
224 months (HR:1.477;95%CI:1.006-2.170;p=0.04). PFS after recurrence was not  
225 significantly different (p=0.868,**Fig.5c**) between patients with CD133<sup>+</sup> and CD133<sup>-</sup>  
226 or between (p=0.252,**Fig.5f**) patients with ALDH1<sup>+</sup> and ALDH1<sup>-</sup>rOC.

227 Median OS for ALDH1<sup>+</sup> and ALDH1<sup>-</sup> patients was 52 and 64 months, respectively  
228 (p=0.402) and median PFI-1 was 9 and 17 months, respectively (p=0.199)(**Fig.5d,5e**).

229 ALDH1/CD133 co-expression in pOCs was found to significantly affect HGSOc  
230 patients' outcome. A significant decrease in OS and PFI has been found in patients  
231 co-expressing ALDH1/CD133 in primary tissue (46 and 9 months, respectively)  
232 compared to patients without biomarker co-expression (68 and 17 months,  
233 respectively) (p=0.019,**Fig.5g**;p=0.015,**Fig.5h**). No significant difference in PFS after  
234 relapse was observed between patients who reported CD133/ALDH1 co-expression or  
235 no co-expression in rOC(p=0.898,**Fig.5i**).

236 On multivariate analysis, the co-expression of ALDH1 and CD133 in pOC, rather  
237 than the single expression of one biomarker, was identified to be an independent  
238 prognostic factor for both PFI (HR:1.638;95%CI:1.033-2.598;p=0.036) and OS  
239 (HR:1.707;95%CI:1.012-2.881;p=0.045) in HGSOc(**Tab.3,4**).

#### 240 Outliers' sub-analysis

241 “Outliers” were considered patients for whom the highest difference between pOC  
242 and rOC could be detected in CD133+cell rate. Three patients were identified: two  
243 reported a difference in CD133+cell rate of -90%(from 90% of CD133+cells at pOC  
244 to 0% at rOC); the first one was a platinum-resistant patient with PFI of 2 months and  
245 OS of 14 months; the second one was a platinum-sensitive patient with PFI of 7  
246 months and OS of 9 months. The third patient showed a difference in CD133+cell  
247 rate of +70%(from 0% of CD133+ at pOC cells to 70% in rOC) with PFI of 15  
248 months (platinum-sensitive) and OS of 44 months.

#### 249 CSC biomarker expression and BRCA status

250 In order to investigate if BRCA mutations could influence CSC biomarker expression,  
251 a subgroup analysis was carried out among 52 patients, whose germline and/or  
252 somatic BRCA status (assessed on pOC and rOC) was available [24]. 40.4% of tested  
253 patients (21/52) had a somatic BRCA mutation in both pOCs and rOCs: 16/52(30.8%)  
254 were BRCA1-mutated (mBRCA1) and 5/52(9.6%) were BRCA2-mutated  
255 (mBRCA2)(**Tab.5**).

256 No significant difference in CD133 and/or ALDH1 expression was found between  
257 BRCA-wild type (BRCA-WT) and BRCA-mutant (mBRCA1/2) tumors(**Tab.6**).

258 Among BRCA-WT patients, no correlation between pOCs and rOCs in CD133+  
259 expression was observed (p=0.088,Spearman coefficient 0.312). Furthermore, in  
260 accordance with results observed in the whole population, paired testing revealed a

261 significant shift from higher levels in pOCs to lower levels in the rOCs  
262 ( $p < 0.0001$ , Wilcoxon test; **Fig. 6a**). In contrast, among mBRCA1/2 patients, no  
263 correlation between pOCs and rOCs ( $p = 0.493$ , Spearman coefficient 0.158), or a  
264 tendency towards a change in CD133+ expression was observed ( $p = 0.167$ , Wilcoxon  
265 test; **Fig. 6b**).

266 Regarding ALDH1 expression, among BRCA-WT patients no correlation between  
267 pOCs and rOCs in ALDH1 IRS was found ( $p = 0.986$ , Spearman coefficient 0.003), as  
268 well as no change in paired testing ( $p = 0.895$ , Wilcoxon test; **Fig. 7a**); also for  
269 mBRCA1/2 patients no difference was observed in ALDH1-IRS between primary and  
270 recurrent patients ( $p = 0.410$ , Spearman coefficient 0.190;  $p = 0.385$ , Wilcoxon  
271 test; **Fig. 7b**).

272 Among BRCA-WT patients, only 1/31 patient (3.2%) showed CD133/ALDH1 co-  
273 expression in both pOCs and rOCs. In 3/31 (9.7%) patients the co-expression was  
274 evidenced in rOCs but not in pOCs. 90% of patients (9/10) reporting CD133/ALDH1  
275 co-expression in pOC lost biomarker co-expression at tumor relapse.

276 Also for mBRCA1/2 patients, only 1/21 (4.8%) patient showed CD133/ALDH1 co-  
277 expression in both pOC and rOC. Two patients (9.5%) had co-expression at recurrent  
278 rather than at primary disease. The difference between BRCA-WT and mBRCA1/2  
279 patients in terms of co-expression loss at rOC was not significant (4/5 vs 9/10,  $p = 1$ ,  
280 Fisher's exact test).

281 Considering patients who were CD133+ and/or ALDH1+ at pOC, no significant  
282 difference could be detected in PFI and OS among BRCA-WT vs mBRCA1/2  
283 cases (**Fig. 8**).

284

285 **DISCUSSION**

286 In the Era of Precision Medicine, huge steps have been taken in the understanding of  
287 HGSOC biology. In this tumor setting, the role of CSC and its clonal evolution during  
288 subsequent disease relapse has been relatively unexplored.

289 This study investigated the changes in CSC biomarkers CD133 and ALDH1  
290 expression in primary and recurrent HGSOCs and showed that CD133+CSCs are  
291 significantly more represented in pOCs rather than rOCs, whereas no significant  
292 changes in terms of ALDH1 expression levels occurred at disease relapse.  
293 Furthermore, CD133 positivity in pOCs significantly correlates with poor survival,  
294 while co-expression of both CD133 and ALDH1 in primary samples independently  
295 predicted poor PFI and OS in HGSOC patients.

296 In 2015, Zhou published a meta-analysis[28], which investigated the prognostic value  
297 of immunohistochemical CD133 expression in OC. Pooled data derived from 1050  
298 patients from 8 studies showed that CD133 positivity significantly correlates with  
299 advanced FIGO stage at diagnosis and with worse OS, in accordance with our  
300 findings, although our population was restricted to HGSOC.

301 Other recent meta-analysis demonstrated that also ALDH1 is a promising prognostic  
302 biomarker for breast[9], head/neck[10], lung[11]and colorectal cancer[12] but its  
303 predictive or prognostic role in OC is still controversial[13,29-31]. In contrast to  
304 CD133, ALDH1 expression is usually low or negative in serous OC compared to  
305 other cancer histotype and more frequent in low FIGO stage tumors[13,29].

306 Previously, Liebscher[21] investigated the prognostic impact of ALDH1 expression  
307 in a homogeneous group of primary HGSOC patients and demonstrated that ALDH1  
308 was an independent prognostic factor for OS. These results differ from our findings,  
309 since in our population ALDH1 did not have an impact on patients' survival.

310 Nevertheless, in Liebscher's population the frequency of FIGO Stage I-II cases was

311 higher than in our population (11.5% vs 7.2%), while the number of optimally  
312 cytoreduced patients was lower (66.3% vs 80.4%).

313 Silva[32] showed that the co-expression of CD133 and ALDH1 correlated with  
314 significant worse PFI and OS in a small cohort of 56 ovarian cancer patients. These  
315 results were in accordance with our findings in a larger HGSOE population.

316 To our knowledge, this is the first study analyzing the evolution of CSC markers in  
317 the largest cohort of primary and recurrent HGSOE patients. Furthermore, the  
318 subanalysis on patients with known BRCA status increases the value of the findings  
319 by taking into consideration the genetic influence of BRCA status on patients'  
320 survival[33-34]and provides a first evidence of the correlation between tumor-  
321 initiating cells and homologous recombination deficiency. Limitation of the study was  
322 the lack of information regarding BRCA1/2 status on all enrolled patients. The  
323 analysis on a cohort of 52 patients could not provide definitive conclusions for this  
324 issue.

325 Interestingly, we observed that 84.6% of our patients' cohort reporting  
326 CD133/ALDH1 co-expression in pOC lost this pathological characteristic at relapse.  
327 Nevertheless, while CSC biomarker expression is significantly correlated with poor  
328 prognosis, it is enigmatic why in a recurrent setting, which represents a more  
329 aggressive step of the disease compared to primary disease, CSCs are less frequently  
330 encountered. Theoretically, CSCs were expected to be much more frequent in rOC  
331 than in the pOC. We hypothesize that the reduction in CSC biomarker expression  
332 does not represent a reduction in CSC number within the tumor sample, but might be  
333 the result of cellular reprogramming occurring in the CSC itself, which might lead to  
334 the loss of CSC biomarker expression. Studies on this issue are still lacking.

335 This study shows that CD133 and ALDH1 as biomarkers can have influence on  
336 HGSOC patients' survival and for the first time suggests that they might be caused by  
337 a phenotypical change during the course of the disease similarly to non stem-like  
338 cancer cells. However, the need for recurrent tumor tissue to be analyzed implied that  
339 this cohort of samples might be not the most representative one for ovarian cancer  
340 patients, due to the fact that most of patients had a platinum sensitive relapse, and  
341 surgical approach at relapse was feasible. For this reason, general conclusion for the  
342 whole recurrent ovarian cancer setting cannot currently be drawn.

343 Another limitation of the study is that these biomarkers, in particular ALDH1, are  
344 broadly expressed, not only by CSCs. The identification of CSC is actually sure only  
345 based on the capacity to build spheroids, on tumor xenograft assay and on serial  
346 transplantation assay, which require fresh tumor tissue. Nevertheless, IHC allowed to  
347 analyze a large cohort of paired tumor tissues and to observe that there is a change in  
348 CSC-associated biomarker expression between primary and relapse disease.

349 Further investigations on larger cohort of paired pOC and rOC samples are warranted,  
350 potentially expanding the scope with inclusion of further candidate CSC markers and  
351 with evaluation of CSCs behavior following neoadjuvant chemotherapy[31,35-36],  
352 in order to reduce mortality of one of the most deadly malignancies of our time.

353

#### 354 **Acknowledgements.**

355 This work was supported by European Community's Seventh Framework Program  
356 under grant agreement No. 279113-2 (OCTIPS). The documentation of clinical and  
357 patient's data was managed with "AlcedisTRIAL the web based documentation  
358 system" of Alcedis GmbH, Winchesterstr. 3, 35394 Giessen, Germany.



359 Elena Ioana Braicu, MD, PhD is participant in the BIH Charité Clinician Scientist  
360 Program funded by the Charité Universitätsmedizin Berlin and the Berlin Institute of  
361 Health.

362 **Role of the Funding Source**

363 European Community's Seventh Framework Program supported this study under the  
364 grant agreement No. 279113-2 (OCTIPS).

365

366 **Conflict of interest statement.**

367 All Authors declare no conflict of interest.

368 **REFERENCES**

- 369 1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber  
370 H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries  
371 in 2012. *Eur J Cancer*. 2013;49:1374-403.  
372
- 373 2. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al.  
374 Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev*  
375 *Cancer*. 2011;11:719-25.  
376
- 377 3. Network CGAR: Integrated genomic analyses of ovarian carcinoma. *Nature*  
378 2011;474:609-15.  
379
- 380 4. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous  
381 ovarian cancer and its clinical impact. *J Clin Oncol*. 2008;26:5284-93.  
382
- 383 5. Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent  
384 concepts on its origin and carcinogenesis. *J Hematol Oncol*. 2012; 5:8.  
385
- 386 6. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A  
387 cell initiating human acute myeloid leukaemia after transplantation into SCID mice.  
388 *Nature*. 1994;367:645-8.  
389
- 390 7. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity,  
391 and uncertainty. *Cancer Cell*. 2012;21:283-96  
392
- 393 8. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards  
394 the root of stemness. *Cancer Lett*. 2013;338:147-57.  
395
- 396 9. Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, et al. ALDH1A1 expression  
397 correlates with clinicopathologic features and poor prognosis of breast cancer  
398 patients: a systematic review and meta-analysis. *BMC Cancer*. 2014;14:444.  
399
- 400 10. Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde  
401 dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. *Oral*  
402 *Oncol*. 2014;50:1144-8.  
403
- 404 11. Wei D, Peng JJ, Gao H, Zhang T, Tan Y, Hu YH. ALDH1 Expression and the  
405 Prognosis of Lung Cancer: A Systematic Review and Meta-Analysis. *Heart Lung*  
406 *Circ*. 2015;24:780-8.  
407
- 408 12. Chen J, Xia Q, Jiang B, Chang W, Yuan W, Ma Z, et al. Prognostic Value of  
409 Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic  
410 Review and Meta-Analysis. *PLoS One*. 2015;10:e0145164.  
411
- 412 13. Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z. The expression of  
413 aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its  
414 clinicopathological associations: a retrospective study. *BMC Cancer*. 2015;15:502.  
415

- 416 14. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor- like cells  
417 contribute to the aggressive behavior of human epithelial ovarian cancer. *Cancer Res*  
418 2005;65:3025-9.  
419
- 420 15. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelial-  
421 mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.  
422 *Human Pathol* 2013, 44(11): 2373–2384;  
423
- 424 16. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T et al.  
425 Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.  
426 *Oncogene* 2009;28:209-18.  
427
- 428 17. Kuroda T, Hirohashi Y, Torigoe T, Yasuda K, Takahashi A, Asanuma H et al.  
429 ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell  
430 adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.  
431 *PLoS One*. 2013, 8(6): e65158;  
432
- 433 18. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM et  
434 al. CD133 expression defines a tumor initiating cell population in primary human  
435 ovarian cancer. *Stem Cells* 2009, 27:2875–2883  
436
- 437 19. HZ L, YS B, WW L and RY L. Expression and clinical significance of CD133  
438 and Notch1 gene in epithelial ovarian carcinoma. *Chin J Clinicians (Electronics*  
439 *Edition)* 2012; 6: 2086-8.  
440
- 441 20. Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, et al. Expression of putative stem  
442 marker nestin and CD133 in advanced serous ovarian cancer. *Neoplasma* 2012; 59:  
443 310-5.  
444
- 445 21. Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, et al.  
446 Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is  
447 characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous  
448 ovarian carcinoma. *Hum Pathol*. 2013;44:1465-71.  
449
- 450 22. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al.  
451 Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem  
452 cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res*.  
453 2009;69:3382-9.  
454
- 455 23. Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, et al.  
456 Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian  
457 cancer. *Eur J Cancer*. 2016;53:51-64.  
458
- 459 24. Patel JN, Sehouli J, Timms K, Solimeno C, Reid EJ, Lanchbury JS, et al.  
460 Characteristics of homologous recombination deficiency (HRD) in paired primary and  
461 recurrent high-grade serous ovarian cancer (HGSOc). *J Clin Oncol* 33, 2015 (suppl;  
462 abstr 5534).  
463
- 464 25. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M et  
465 al. Clinical trials in recurrent ovarian cancer. *Int J Gynecol Cancer*. 2011;21:771-5.


466  
467 26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al.  
468 New response evaluation criteria in solid tumours: Revised RECIST guideline  
469 (version 1.1). *European Journal of Cancer* 2009; 45:228-247.  
470  
471 27. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et  
472 al. Definitions for response and progression in ovarian cancer clinical trials  
473 incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer  
474 Intergroup (GCIg). *Int J Gynecol Cancer*. 2011;21:419-23.  
475  
476 28. Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M. Prognostic value of cancer stem  
477 cell marker CD133 in ovarian cancer: a meta-analysis. *Int J Clin Exp Med*.  
478 2015;8:3080-8.  
479  
480 29. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, et al. ALDH1 expression  
481 correlates with favorable prognosis in ovarian cancers. *Mod Pathol*. 2009;22:817-23.  
482  
483 30. Chen PX, Li QY, Yang Z. Musashi-1 Expression is a Prognostic Factor in  
484 Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression. *Pathol Oncol*  
485 *Res*. 2015;21:1133-40.  
486  
487 31. Ayub TH, Keyver-Paik MD, Debald M, Rostamzadeh B, Thiesler T, Schröder L,  
488 et al. Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy  
489 predicts treatment resistance and prognosticates poor outcome in ovarian cancer.  
490 *Oncotarget*. 2015;6:16437-48.  
491  
492 32. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde  
493 dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem  
494 cells that portend poor patient survival. *Cancer Res*. 2011;71:3991-4001.  
495  
496 33. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of  
497 BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene  
498 mutator phenotype in patients with ovarian cancer. *JAMA*, 2011. 306:1557-65.  
499  
500 34. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY et al.  
501 Association between BRCA1 and BRCA2 mutations and survival in women with  
502 invasive epithelial ovarian cancer. *JAMA*, 2012. 307:382-9.  
503  
504 35. Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF, et al. 5-Fluorouracil  
505 chemotherapy of gastric cancer generates residual cells with properties of cancer stem  
506 cells. *Int J Biol Sci*. 2015;11:284-94.  
507  
508 36. Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T, et  
509 al. Immunohistochemical analysis of cancer stem cell markers in pancreatic  
510 adenocarcinoma patients after neoadjuvant chemoradiotherapy. *BMC Cancer*.  
511 2014;14:687.  
512  
513  
514  
515

516 **LEGEND TO TABLES AND FIGURES**


- 517 • Table 1: Patients' characteristics
- 518 • Table 2: Association of CSCs biomarkers expression with patients' clinico-  
519 pathological characteristics (primary tumors).
- 520 • Table 3: Multivariate analysis for PFI
- 521 • Table 4: Multivariate analysis for OS
- 522 • Table 5: patients' germline and/or somatic (primary and recurrent tumor)  
523 BRCA status.
- 524 • Table 6: Association of CSCs biomarkers expression with patients' BRCA  
525 status (primary tumors).
- 526
- 527 • Figure 1: CD133 immunohistochemistry staining. Primary tumors, CD133+  
528 (a) and CD133- (b) samples; recurrent tumors, CD133+ (c) and CD133- (d)  
529 samples.
- 530 • Figure 2: CD133+ cell rates among primary and recurrent tumors (box plot – a  
531 - and line plot – b).
- 532 • Figure 3: ALDH1 immunohistochemistry staining. ALDH1 IRS at primary (a)  
533 and recurrent (d) tumors. Primary tumors, ALDH1+ (b) and ALDH1- (c)  
534 samples; recurrent tumors, ALDH1+ (e) and ALDH1- (f) samples.
- 535 • Figure 4: ALDH1 IRS among primary and recurrent tumors (box plot – a - and  
536 line plot – b).
- 537 • Figure 5: CD133 and/or ALDH1 status in primary (a, b, d, e, g, h) and  
538 recurrent (c, f, i) samples and survival.
- 539 • Figure 6: CD133+ cell rates among primary and recurrent tumors (box plot,  
540 BRCA-WT- a - and box plot mBRCA1/2 – b).
- 541 • Figure 7: ALDH1 IRS among primary and recurrent tumors (box plot BRCA-  
542 WT- a - and box plot mBRCA1/2 – b).
- 543 • Figure 8: CD133+ and/or ALDH1+ and survival in BRCA-WT and  
544 mBRCA1/2 patients (primary tumors).

Figure 1


a



b



c



d




Figure 2







Figure 3

a




ALDH1 IRS primary


b



c




d



ALDH1 IRS recurrent

e



f







Figure 4

a



b




Figure 5




Figure 6





Figure 7





Figure 8




Table 1

PARAMETER	
PATIENTS (n.)	112
AGE Median (range)	56y (33-77y)
FIGO STAGE (%)	
- I	2 (1.8%)
- II	6 (5.4%)
- III	93 (83%)
- IV	11 (9.8%)
RESIDUAL TUMOR AFTER PRIMARY DEBULKING SURGERY:	
- No residual tumor	90 (80.4%)
- Residual Tumor	22 (19.6%)
PLATINUM SENSITIVITY STATUS AFTER PRIMARY TREATMENT	
- Platinum sensitive	90 (80.4%)
- Platinum resistant	18 (16.1%)
- Missing	4 (3.5%)
PLATINUM SENSITIVITY STATUS AFTER TREATMENT FOR DISEASE RELAPSE	
- Platinum sensitive	59 (52.7%)
- Platinum resistant	12 (10.7%)
- Missing	41(36.6%)

Table 2

Clinico-pathological factors	Total N°	CD133			ALDH1			CD133 and ALDH1 coexpression		
		Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P
Patients' Age										
< 56y	54	27 (50%)	27 (50%)	0.855	18 (33%)	36 (67%)	0.288	11 (20%)	43 (80%)	0.492
≥ 56y	58	28 (48%)	30 (52%)		25 (43%)	33 (57%)		15 (26%)	43 (74%)	
FIGO STAGE										
I/II	8	0	8 (100%)	<b>0.006</b>	3 (38%)	5 (62%)	1.000	0	8 (100%)	0.194
III/IV	104	55 (53%)	49 (47%)		40 (39%)	64 (61%)		26 (25%)	78 (75%)	
RESIDUAL TUMOR AFTER FIRST CYTOREDUCTIVE SURGERY										
No residual	90	42 (47%)	48 (53%)	0.346	35 (39%)	55 (61%)	1.000	20 (22%)	70 (78%)	0.586
Any residual	22	13 (59%)	9 (41%)		8 (36%)	14 (64%)		6 (27%)	16 (73%)	
PLATINUM SENSITIVITY STATUS AFTER PRIMARY TREATMENT										
Platinum sensitive	90	43 (48%)	47 (52%)	0.439	33 (37%)	57 (63%)	0.303	19 (21%)	71 (79%)	0.357
Platinum resistant	18	7 (39%)	11 (61%)		9 (50%)	9 (50%)		6 (33%)	12 (67%)	

Table 3

## PROGRESSION FREE INTERVAL

	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS	
	HR (95% CI)	P	HR (95% CI)	P
Age	1.003 (0.983-1.024)	0.774		
FIGO Stage (III/IV vs I/II)	2.019 (0.907-4.496)	0.085	1.856 (0.826-4.169)	0.134
Residual Tumor (any residual vs no residual)	1.026 (0.625-1.684)	0.919		
CD133/ALDH1 coexpression (positive vs negative)	1.729 (1.093-2.733)	0.019	1.638 (1.033-2.598)	<b>0.036</b>



Table 4

OVERALL SURVIVAL				
	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS	
	HR (95% CI)	P	HR (95% CI)	P
Age	1.011 (0.985-1.038)	0.404		
FIGO Stage (III/IV vs I/II)	1.465 (0.533-4.020)	0.459		
Residual Tumor (any residual vs no residual)	1.632 (0.973-2.736)	0.063	1.272 (0.725-2.231)	0.401
Platinum sensitivity status after primary treatment (platinum resistant vs platinum sensitive)	3.394 (1.927-5.978)	<0.001	2.907 (1.594-5.302)	<b>&lt;0.001</b>
CD133/ALDH1 coexpression (positive vs negative)	1.799 (1.089-2.971)	0.022	1.707 (1.012-2.881)	<b>0.045</b>

Table 5

PATIENT ID	GERMLINE BRCA STATUS	SOMATIC BRCA STATUS – PRIMARY TUMOR	SOMATIC BRCA STATUS – RECURRENT TUMOR
B001	mBRCA1	mBRCA1	mBRCA1
B002	WT	WT	WT
B003	WT	WT	WT
B006	N/A	WT	WT
B007	N/A	WT	WT
B009	N/A	WT	WT
B012	N/A	WT	WT
B015	N/A	WT	WT
B019	WT	mBRCA2	mBRCA2
B021	N/A	WT	WT
B022	N/A	WT	WT
B024	mBRCA1	mBRCA1	mBRCA1
B025	N/A	WT	WT
B026	N/A	WT	WT
B028	mBRCA1	mBRCA1	mBRCA1
B029	mBRCA1	mBRCA1	mBRCA1
B030	N/A	WT	WT
B032	WT	WT	WT
B037	N/A	WT	WT
B041	mBRCA1	mBRCA1	mBRCA1
B044	N/A	WT	WT
B045	N/A	mBRCA1	mBRCA1
B048	WT	WT	WT
B050	WT	WT	WT
B051	N/A	mBRCA2	mBRCA2
B052	WT	WT	WT
B053	N/A	WT	WT
B054	N/A	WT	WT
B062	N/A	WT	WT
B063	N/A	mBRCA2	mBRCA2
B065	WT	WT	WT
B068	N/A	mBRCA1	mBRCA1
B069	N/A	WT	WT
B071	N/A	mBRCA1	mBRCA1
B077	mBRCA2	mBRCA2	mBRCA2
B080	mBRCA2	mBRCA2	mBRCA2
B081	WT	mBRCA1	mBRCA1
B082	N/A	mBRCA1	mBRCA1
B085	N/A	mBRCA1	mBRCA1
B087	mBRCA1	mBRCA1	mBRCA1
B088	N/A	WT	WT
B090	N/A	mBRCA1	mBRCA1
B093	N/A	WT	WT
B094	N/A	mBRCA1	mBRCA1
B097	N/A	mBRCA1	mBRCA1
B098	N/A	WT	WT
B099	N/A	WT	WT
B100	N/A	WT	WT
L007	WT	WT	WT
L010	WT	WT	WT
L017	WT	WT	WT
L020	mBRCA1	mBRCA1	mBRCA1

Table 6

BRCA status	Total N°	CD133			ALDH1			CD133 and ALDH1 coexpression		
		Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P	Positive (%)	Negative (%)	P
BRCA-WT	31	21 (68%)	10 (32%)	0.769	13 (42%)	18 (58%)	0.575	10 (32%)	21 (68%)	0.551
mBRCA1/2	21	13 (62%)	8 (38%)		7 (33%)	14 (67%)		5 (24%)	16 (76%)	